Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 20/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 1/20 | 1.00 |
| ▸ | PRKACA | P17612 | 4/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.73 |
| ▸ | CIT | O14578 | 1/20 | 0.62 |
| ▸ | JAK2 | O60674 | 1/20 | 0.62 |
| ▸ | FLT3 | P36888 | 1/20 | 0.62 |
| ▸ | GSK3B | P49841 | 1/20 | 0.62 |
| ▸ | JAK3 | P52333 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL439527 | 0.91 | ROCK1 (0.83) | ROCK1ROCK2PRKACACYP3A4CIT | |
| SCHEMBL439528 | 0.91 | ROCK1 (0.83) | ROCK1ROCK2PRKACACYP3A4CIT | |
| SCHEMBL3254520 | 0.85 | ROCK1 (1.00) | ROCK1ROCK2PRKACACYP3A4CIT | |
| SCHEMBL13357727 | 0.85 | ROCK1 (0.74) | ROCK1ROCK2PRKACACYP3A4CIT | |
| SCHEMBL13887734 | 0.85 | ROCK1 (1.00) | ROCK1ROCK2CYP3A4CITJAK2 | |
| SCHEMBL3254509 | 0.84 | ROCK1 (0.75) | ROCK1ROCK2PRKACACYP3A4 | |
| SCHEMBL13887799 | 0.83 | ROCK1 (0.87) | ROCK1ROCK2PRKACACYP3A4CIT | |
| SCHEMBL438725 | 0.82 | ROCK1 (0.84) | ROCK1ROCK2PRKACACYP3A4CIT | |
| SCHEMBL3250252 | 0.82 | ROCK1 (1.00) | ROCK1ROCK2PRKACACYP3A4CIT | |
| SCHEMBL6204175 | 0.82 | ROCK1 (0.76) | ROCK1ROCK2PRKACACYP3A4CIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558607-B1 | COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | VERTEX PHARMA (US) | 2010-05-05 | — | — | EP | disclosed |
| US-20040122016-A1 | Compositions useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122016-A1 | Compositions useful as inhibitors of rock and other protein kinases | ROCK1, ROCK2, PRKCH | ROCK1 1/4885ROCK2 2/4885PRKACA 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.